ArcticZymes Technologies (AZT) Stock Overview
A life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AZT from our risk checks.
AZT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ArcticZymes Technologies ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 19.80 |
| 52 Week High | NOK 31.40 |
| 52 Week Low | NOK 14.50 |
| Beta | 0.52 |
| 1 Month Change | 4.21% |
| 3 Month Change | -15.02% |
| 1 Year Change | 21.85% |
| 3 Year Change | -48.44% |
| 5 Year Change | -82.16% |
| Change since IPO | -20.80% |
Recent News & Updates
Recent updates
Results: ArcticZymes Technologies ASA Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 15
Subdued Growth No Barrier To ArcticZymes Technologies ASA (OB:AZT) With Shares Advancing 25%
Jan 08Are Investors Undervaluing ArcticZymes Technologies ASA (OB:AZT) By 50%?
Jan 07More Unpleasant Surprises Could Be In Store For ArcticZymes Technologies ASA's (OB:AZT) Shares After Tumbling 28%
Nov 20What ArcticZymes Technologies ASA's (OB:AZT) 50% Share Price Gain Is Not Telling You
Aug 15ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up
Mar 11ArcticZymes Technologies ASA's (OB:AZT) Intrinsic Value Is Potentially 43% Above Its Share Price
Feb 15
Transition To Solution Provider Will Accelerate Market Penetration By Late 2025
ArcticZymes is shifting from raw materials to solutions, aiming for revenue growth through closer customer interactions and market penetration by late 2025.Take Care Before Jumping Onto ArcticZymes Technologies ASA (OB:AZT) Even Though It's 25% Cheaper
Nov 28Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Nov 12ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Nov 09The Price Is Right For ArcticZymes Technologies ASA (OB:AZT) Even After Diving 28%
Aug 31ArcticZymes Technologies' (OB:AZT) Solid Earnings May Rest On Weak Foundations
Aug 30ArcticZymes Technologies ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 25Earnings Miss: ArcticZymes Technologies ASA Missed EPS By 17% And Analysts Are Revising Their Forecasts
May 12ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 08ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
Feb 02Shareholder Returns
| AZT | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -0.5% | -5.9% | -1.1% |
| 1Y | 21.8% | 48.9% | 27.1% |
Return vs Industry: AZT underperformed the Norwegian Biotechs industry which returned 48.9% over the past year.
Return vs Market: AZT underperformed the Norwegian Market which returned 27.1% over the past year.
Price Volatility
| AZT volatility | |
|---|---|
| AZT Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in NO Market | 11.1% |
| 10% least volatile stocks in NO Market | 3.2% |
Stable Share Price: AZT has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: AZT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 53 | Michael Akoh | www.arcticzymes.com |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids.
ArcticZymes Technologies ASA Fundamentals Summary
| AZT fundamental statistics | |
|---|---|
| Market cap | NOK 1.01b |
| Earnings (TTM) | NOK 9.88m |
| Revenue (TTM) | NOK 118.21m |
Is AZT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZT income statement (TTM) | |
|---|---|
| Revenue | NOK 118.21m |
| Cost of Revenue | NOK 4.68m |
| Gross Profit | NOK 113.52m |
| Other Expenses | NOK 103.64m |
| Earnings | NOK 9.88m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 96.04% |
| Net Profit Margin | 8.36% |
| Debt/Equity Ratio | 0% |
How did AZT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/27 14:02 |
| End of Day Share Price | 2026/04/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ArcticZymes Technologies ASA is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Carnegie |
| Viktor Sundberg | Nordea Markets |